Yahoo Search Busca da Web

Resultado da Busca

  1. Há 19 horas · Commonly known as Lou Gehrig's disease, ALS affects roughly 60,000 people in the U.S. and Europe. Shares of Biogen and Ionis were each down nearly 2% in premarket trading.

  2. Há 6 horas · Commonly known as Lou Gehrig's disease, ALS affects roughly 60,000 people in the U.S. and Europe. Shares of Biogen and Ionis were each down nearly 2% in premarket trading.

  3. Há 4 horas · ALS, also known as Lou Gehrig's disease, is a terminal neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to progressive muscle weakness and paralysis. The brain eventually loses communication with muscles, which affects a person's movement, speech and eventually breathing.

  4. Há 19 horas · ALS, commonly known as Lou Gehrig’s disease, is a rare and fatal neurodegenerative disease that affects voluntary control of the arms and legs and leads to breathing trouble. The companies’ drug, BIIB105, did not succeed in significantly reducing neurodegeneration or improve functional measures such as breathing in patients, they said.

  5. Há 19 horas · ALS, commonly known as Lou Gehrig's disease, is a rare and fatal neurodegenerative disease that affects voluntary control of the arms and legs and leads to breathing trouble. The companies' drug, BIIB105, did not succeed in significantly reducing neurodegeneration or improve functional measures such as breathing in patients, they said.

  6. Há 6 horas · First drop in overdose deaths in 6 years, US preliminary data shows. The number of deaths from drug overdose fell 3% to 107,543 in 2023 from the previous year, according to preliminary data from the U.S. Centers for Disease Control and Prevention (CDC) released on Wednesday. States including Nebraska, Kansas, Indiana and Maine saw declines of ...

  7. Há 5 horas · Biogen and Ionis Pharmaceuticals saw their stocks decline after announcing the discontinuation of their experimental ALS treatment, BIIB105. The decision came after the drug failed to show significant improvement in patients during an early-to-mid stage study. ALS, also known as Lou Gehrig's disease, is a rare and fatal neurodegenerative condition.